Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25624611 | 0.91 | MAP3K12 (0.34) | — | |
| SCHEMBL25613080 | 0.88 | LRRK2 (0.40) | LRRK2MAPK1GRM4MAPK8MAPK9 | |
| SCHEMBL25625631 | 0.87 | SGK1 (0.31) | — | |
| SCHEMBL24005908 | 0.85 | LRRK2 (0.39) | LRRK2MAPK1GRM4MAPK8MAPK9 | |
| SCHEMBL25624691 | 0.84 | PDE4B (0.34) | LRRK2MAPK1GRM4BRAF | |
| SCHEMBL25624775 | 0.81 | TDO2 (0.38) | LRRK2SOS1 | |
| SCHEMBL25613081 | 0.78 | LRRK2 (0.41) | LRRK2MAPK1GRM4MAPK8MAPK9 | |
| SCHEMBL25613064 | 0.78 | TTK (0.33) | MAPK1CNR2 | |
| SCHEMBL25626737 | 0.75 | LRRK2 (0.34) | LRRK2 | |
| SCHEMBL25613180 | 0.73 | KCNH2 (0.34) | LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | LRRK2 882/4885MAPK1 2612/4885GRM4 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.